Evogene (EVGN) Retained Earnings (2012 - 2025)
Evogene (EVGN) posted Retained Earnings of -$282.6 million for Q4 2025, down 0.51% sequentially from -$281.1 million in Q2 2025, and down 3.1% YoY from -$291.6 million in Q4 2024.
Evogene (EVGN) Retained Earnings (2012 - 2025) Analysis & Trends
Evogene has reported Retained Earnings for 14 years, with the latest figure at -$282.6 million in Q4 2025.
- Quarterly Retained Earnings fell 3.1% year-over-year to -$282.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$282.6 million (down 3.1% YoY) and the FY2025 annual result came in at -$282.6 million, down 3.1% from the prior year.
- Retained Earnings declined to -$282.6 million in Q4 2025 per EVGN's latest filing, from -$281.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$185.9 million in Q1 2021 and troughed at -$282.6 million in Q4 2025.
- A 5-year average of -$240.3 million and a median of -$243.5 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings fell 16.7% in 2022, then declined 3.1% in 2025.
- Over 5 years, Retained Earnings stood at -$207.1 million in 2021, then dropped by 12.86% to -$233.7 million in 2022, then decreased by 10.22% to -$257.6 million in 2023, then declined by 6.4% to -$274.1 million in 2024, then decreased by 3.1% to -$282.6 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$282.6 million, -$281.1 million, and -$274.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -282.56 Mn |
| Jun 30, 2025 | -281.12 Mn |
| Dec 31, 2024 | -274.07 Mn |
| Sep 30, 2024 | -274.50 Mn |
| Jun 30, 2024 | -266.87 Mn |
| Mar 31, 2024 | -261.45 Mn |
| Dec 31, 2023 | -257.59 Mn |
| Sep 30, 2023 | -250.99 Mn |
| Jun 30, 2023 | -247.00 Mn |
| Mar 31, 2023 | -239.98 Mn |
| Dec 31, 2022 | -233.71 Mn |
| Sep 30, 2022 | -230.71 Mn |
| Jun 30, 2022 | -224.17 Mn |
| Mar 31, 2022 | -215.34 Mn |
| Dec 31, 2021 | -207.07 Mn |
| Sep 30, 2021 | -199.70 Mn |
| Jun 30, 2021 | -192.09 Mn |
| Mar 31, 2021 | -185.88 Mn |
| Dec 31, 2020 | -179.28 Mn |
| Sep 30, 2020 | -171.15 Mn |